سعر إمباجلوتك 25 مجم 2024

Tablets empagliflozin 25 mg; 30 tablets (Mash Premiere).

• Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (US label for equivalent formulation).Population: Adults with type 2 diabetesDailyMed (U.S. NLM)
• US Jardiance also indicated to reduce risk of cardiovascular death and hospitalization for heart failure / CKD progression in labeled adult populations (see full USPI).Population: Adults per US labeled CV/CKD indicationsDailyMed (U.S. NLM)

• Common: urinary tract infection, genital mycotic infection, increased urination, thirst, nasopharyngitis; with metformin also GI upset (diarrhea, nausea). Laboratory: increased LDL-C, increased hematocrit (US labels).International label, equivalent formulation · DailyMed (U.S. NLM)

• History of serious hypersensitivity to empagliflozin (and linagliptin if combination) or any product component; patients on dialysis (US SGLT2/DPP-4 combination labels).International label, equivalent formulation · DailyMed (U.S. NLM)

• Ketoacidosis (including euglycemic), volume depletion, urosepsis/pyelonephritis, genital mycotic infections, hypoglycemia with insulin/sulfonylurea, necrotizing fasciitis of the perineum (Fournier gangrene) reported with SGLT2 inhibitors (US labels).International label, equivalent formulation · DailyMed (U.S. NLM)

• Insulin or insulin secretagogues (e.g. sulfonylureas)MajorIncreased risk of hypoglycemia; consider lower dose of insulin/secretagogue when coadministered.DailyMed (U.S. NLM)

• US labels advise against use in second/third trimester based on animal data showing adverse renal effects of SGLT2 inhibitors; counsel and use alternative therapy when pregnancy recognized.International label, equivalent formulation · DailyMed (U.S. NLM)
• Not recommended while breastfeeding (US labels: risk of serious adverse reactions in breastfed infant from SGLT2/metformin exposure).International label, equivalent formulation · DailyMed (U.S. NLM)

• Empagliflozin: Inhibits SGLT2 in the proximal renal tubule, reducing renal reabsorption of filtered glucose and lowering the renal threshold for glucose, thereby increasing urinary glucose excretion (US label).